Pipeline Overview

Category	Disease	Target	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Market
Virology: Liver
	Hepatitis C Virus	Protease	Glecaprevir*
	Hepatitis B Virus	Core	EDP-514**
Virology: Respiratory
	Respiratory Syncytial Virus	N-Protein	Zelicapavir (EDP-938) Pediatrics
			RSV	N-Protein	Zelicapavir (EDP-938) High Risk Adults
		RSV	L-Protein	EDP-323 (challenge study)
	COVID-19	3CL Protease	EDP-235** SPRINT
Immunology: Type 2 Immune Diseases
	Chronic Spontaneous Urticaria***	KIT
	Atopic Dermatitis***	STAT6

Virology: Liver
Hepatitis C Virus Protease
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Glecaprevir*
Hepatitis B Virus Core
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-514**

Virology: Respiratory
Respiratory Syncytial VirusN-Protein
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Zelicapavir (EDP-938) Pediatrics
Respiratory Syncytial Virus N-Protein
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Zelicapavir (EDP-938) High Risk Adults
Respiratory Syncytial Virus L-Protein
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-323 (challenge study)
COVID-19 3CL Protease
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-235** SPRINT

Immunology: Type 2 Immune Diseases
Chronic Spontaneous Urticaria*** KIT
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Atopic Dermatitis*** STAT6
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market

*Fixed-dose antiviral combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET® (U.S.) and MAVIRET® (ex-U.S.).
**Continued development dependent on a future collaboration.
***Initial indications. Potential future indications include asthma, chronic inducible urticaria (CIndU), eosinophilic esophagitis (EoE), prurigo nodularis (PN), and others.